Tag «PHASE 3»

Azeliragon

Azeliragon C32H38ClN3O2, 532.1 g/mol CAS 603148-36-3 TTP488 UNII-LPU25F15UQ LPU25F15UQ TTP-488; PF-04494700 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine MOA：RAGE inhibitor Indication：Alzheimer’s disease (AD) Status：Phase III (Active), Dementia, Alzheimer’s type Company：vTv Therapeutics (Originator) Azeliragon Azeliragon is in phase III clinical for the treatment of Alzheimer’s type dementia. Azeliragon was originally by TransTech Pharma (now vTv Therapeutics), then licensed to Pfizer in 2006. Pfizer discontinued the research …

Fasoracetam

Fasoracetam Molecular FormulaC10H16N2O2 Average mass196.246 Da (5R)-5-(1-Piperidinylcarbonyl)-2-pyrrolidinone (5R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one 110958-19-5 [RN] 2-Pyrrolidinone, 5-(1-piperidinylcarbonyl)-, (5R)- 7708, UNII: 42O8UF5CJB NS 105 N-(5-Oxo-D-prolyl)piperidine (+)-1-(((R)-5-Oxo-2-pyrrolidinyl)carbonyl)piperidine AEVI GENOMIC MEDICINE, INC. [US/US]; 435 Devon Park Drive, Suite 715 Wayne, Pennsylvania 19087, US Fasoracetam is a research chemical of the racetam family.[3] It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use …

VX-445, Elexacaftor, エレクサカフトル

VX-445, Elexacaftor, エレクサカフトル 597.658 g/mol, C26H34F3N7O4S 3-Pyridinecarboxamide, N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)- N-[(1,3-Dimethyl-1H-pyrazol-4-yl)sulfonyl]-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]-3-pyridinecarboxamide 3-Pyridinecarboxamide, N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)- UNII-RRN67GMB0V RRN67GMB0V VX-445 WHO 11180 Cas 2216712-66-0 WHO 11180 Treatment of cystic fibrosis, CFTR modulator Elexacaftor is under investigation in clinical trial NCT03525548 (A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)). Cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR …

MITAPIVAT

MITAPIVAT CAS 1260075-17-9 MF C24H26N4O3S MW 450.55 UPDATE…. FDA APPROVE 2/17/2022 To treat hemolytic anemia in pyruvate kinase deficiency, Pyrukynd митапиват [Russian] [INN] ميتابيفات [Arabic] [INN] 米他匹伐 [Chinese] [INN] 10226 1260075-17-9 [RN] 2WTV10SIKH AG-348 8-Quinolinesulfonamide, N-[4-[[4-(cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]- N-[4-[[4-(Cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-8-quinolinesulfonamide Originator Agios Pharmaceuticals Class Antianaemics; Piperazines; Quinolines; Small molecules; Sulfonamides Mechanism of Action Pyruvate kinase stimulants Orphan Drug Status Yes – Inborn error metabolic disorders New Molecular Entity Yes Phase III Inborn …

RISDIPLAM , リスジプラム

RISDIPLAM RG-7916, RO-7034067, リスジプラム Formula C22H23N7O Cas 1825352-65-5 Mol weight 401.4643 US9969754 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one WHO 10614 RG-7916 HY-109101 RO7034067 CS-0039501 EX-A2074 RG7916 The compound was originally claimed in WO2015173181 , for treating spinal muscular atrophy (SMA). Roche , under license from PTC Therapeutics , and Chugai , are developing risdiplam (RO-7034067; RG-7916), a small-molecule survival motor neuron …

FOSTEMSAVIR ,фостемсавир , فوستيمسافير , 磷坦姆沙韦 ,ホステムサビル;

FOSTEMSAVIR ,фостемсавир , فوستيمسافير , 磷坦姆沙韦 ,ホステムサビル; Fostemsavir GSK3684934 CAS 864953-29-7 Molecular FormulaC25H26N7O8P Average mass583.490 Da ホステムサビル; [3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate {3-[(4-Benzoyl-1-piperazinyl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate [ACD/IUPAC Name] 1,2-Ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]- [ACD/Index Name] 10292 864953-29-7 [RN] фостемсавир [Russian] [INN] فوستيمسافير [Arabic] [INN] 磷坦姆沙韦 [Chinese] [INN] BMS 663068 BMS663068 Fostemsavir tromethamine UNII-2X513P36U0 Fostemsavir tromethamine [USAN], CAS 864953-39-9, MW 704.6303 Prodrug of BMS-626529, an HIV-1 attachment inhibitor. BMS-663068 is an HIV-1 …

IMETELSTAT

IMETELSTAT CAS 868169-64-6, N163L Molecular Formula, C148-H211-N68-O53-P13-S13, Molecular Weight, 4610.2379, Nucleic Acid Sequence Sequence Length: 135 a 1 c 4 g 3 tmodified DNA d(3′-amino-3′-deoxy-P-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A) 5′-[O-[2-hydroxy-3-[(1-oxohexadecyl)amino]propyl] hydrogen phosphorothioate] PHASE 3, GERON, Myelodysplasia IMETELSTAT SODIUM CAS 1007380-31-5, GRN163L, GRN 163L Sodium Salt Molecular Formula: C148H198N68Na13O53P13S13 Molecular Weight: 4895.941 g/mol 5′-(O-(2-hydroxy-3-((1-oxohexadecyl)amino)propyl)phosphorothioate)-d(3′-amino-3′-deoxy-p-thio)(t-a-g-g-g-t-t-a-g-a-c-a-a), sodium salt (13) DNA, d(3′-amino-3′-deoxy-p-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5′-(o-(2-hydroxy-3-((1-oxohexadecyl)amino)propyl) hydrogen phosphorothioate), …

Relugolix レルゴリクス

Relugolix (TAK-385), RVT 601 レルゴリクス Formula C29H27F2N7O5S CAS 737789-87-6 Mol weight UNII 623.6304 UNII-P76B05O5V6 2019/1/8 PMDA JAPAN APPROVED, Relumina 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N’-methoxy- 737789-87-6 [RN] 9628 P76B05O5V6 Originator Takeda Developer Myovant Sciences; Takeda; Takeda Oncology Class Analgesics; Antineoplastics; Ketones; Pyrimidines; Small molecules Mechanism of Action LHRH receptor antagonists Preregistration Uterine leiomyoma Phase III Pain; Prostate cancer No development reported Solid tumours 08 Nov 2018 Myovant announces …

Omecamtiv mecarbil オメカムティブメカビル

Omecamtiv mecarbil Molecular FormulaC20H24FN5O3 Average mass401.435 Da 4-[2-fluoro-3-[(6-methyl-3-pyridyl)carbamoylamino]benzyl]piperazine-1-carboxylic acid methyl ester AMG 423 AMG-423 CK1827452 CK-1827452; CK1827452 Cladribine [BAN] [INN] [JAN] [USAN] [Wiki] methyl 4-(2-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate 1-Piperazinecarboxylic acid, 4-[[2-fluoro-3-[[[(6-methyl-3-pyridinyl)amino]carbonyl]amino]phenyl]methyl]-, methyl ester 2M19539ERK オメカムティブメカビル 873697-71-3 [RN] 9088 Methyl 4-(2-fluoro-3-{[(6-methyl-3-pyridinyl)carbamoyl]amino}benzyl)-1-piperazinecarboxylate NMR https://file.selleckchem.com/downloads/nmr/S262301-CK-1827452-NMR-Selleck.pdf In January 2019, Cytokinetics and licensees Amgen and Servier are developing oral modified- and immediate-release formulations of the cardiac myosin activator omecamtiv mecarbil (phase …

SELETALISIB, селеталисиб , سيلستاليسيب , 司来利塞 ,

SELETALISIB CAS 1362850-20-1 UCB-5857 , Plaque psoriasis,Sjoegren’s syndrome,Immunodeficiency disorders PHASE 3 UCB 23H14ClF3N6O , 482.85 Phosphatidylinositol 3 kinase delta (PI3Kδ) inhibitors 10023 1362850-20-1 [RN] N-{(1R)-1-[8-Chlor-2-(1-oxido-3-pyridinyl)-3-chinolinyl]-2,2,2-trifluorethyl}pyrido[3,2-d]pyrimidin-4-amine N—{(R)-1-[8-Chloro-2-(pyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl}N-(1-oxypyrido-[3,2-d]pyrimidin-4-yl)amine Pyrido[3,2-d]pyrimidin-4-amine, N-[(1R)-1-[8-chloro-2-(1-oxido-3-pyridinyl)-3-quinolinyl]-2,2,2-trifluoroethyl]- 3-{8-chloro-3-[(1R)-2,2,2-trifluoro-1-({pyrido[3,2-d]pyrimidin-4-yl}amino)ethyl]quinolin-2-yl}pyridin-1-ium-1-olate селеталисиб [Russian] [INN] سيلستاليسيب [Arabic] [INN] 司来利塞 [Chinese] [INN] N-[(1R)-1-[8-chloro-2-(1-oxidopyridin-1-ium-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine Seletalisib has been used in trials studying the treatment and basic science of Primary Sjogren’s Syndrome. Originator UCB Class Anti-inflammatories; Small molecules Mechanism of Action Immunomodulators; Phosphatidylinositol 3 kinase …